瑞舒伐他汀钙对高血压患者血管活性物质、脉压指数、颈动脉内膜中层厚度的影响及相关性分析  

The effects of rosuvastatin on the changes of vasoactive substances,pulse pressure index and intima media thickness in patients with hypertension

作　　者：李莉[1] 周元丽[2] 张雪晶[1] 刘丽[1] 王晓琳[3] 

机构地区：[1]山东大学附属济南市中心医院心内科,250013 [2]山东大学附属济南市中心医院保健科,250013 [3]山东大学医学院

出　　处：《疑难病杂志》2014年第10期991-994,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金青年科学基金项目(No.81200211);山东省优秀中青年科学家科研奖励基金(No.BS2012SW003);济南市科技明星计划(No.20120144)

摘　　要：目的评价瑞舒伐他汀钙对高血压患者血管活性物质、脉压指数(PPI)及颈动脉内膜中层厚度(IMT)的影响及相关性。方法选择高血压患者80例,随机分成观察组和对照组,每组各40例。观察组在原降压药物的基础上加服瑞舒伐他汀钙(10mg/d),对照组则继续服用原降压药物不变,于治疗前及治疗1个月、6个月、12个月分别检测患者的血清高敏C反应蛋白(hs—CRP)、血同型半胱氨酸(Hcy)、血压、PPI及颈动脉IMT。结果 2组治疗前血压、PPI、血清hs—CRP、Hcy及IMT比较差异无统计学意义(P>0.05)。与治疗前相比,2组治疗1个月后肱动脉的收缩压、PP均有明显的降低(P<0.05),而舒张压无显著改变;对照组PPI在治疗12个月后差异有统计学意义(P<0.05),观察组治疗1个月后PPI有明显的降低(P<0.05)。与对照组相比,观察组治疗6个月后收缩压、PP降低更明显(P<0.05),而PPI治疗1、6、12个月后与同期对照组相比差异均有统计学意义(P<0.05)。观察组治疗后血清hs-CRP、Hcy浓度及IMT均有明显的降低(P<0.05),与对照组相比,观察组hs—CRP治疗1、6、12个月后差异有统计学意义(P<0.05);Hcy治疗6、12个月后差异有统计学意义(P<0.05),IMT治疗6个月后差异有统计学意义(P<0.05)。相关性分析表明,PPI与血清hs-CRP、Hcy浓度及颈动脉IMT均呈正相关(分别为r=0.606、0.583、0.672,P<0.05)。结论瑞舒伐他汀能显著降低高血压患者血管活性物质水平,改善IMT并降低PPI,从而起到抑制炎性反应、缩小动脉粥样硬化斑块,改善血管弹性的作用。Objective To evaluate the effect of rosuvastatin calcium on vasoactive substances, pulse pressure index （PPI） and carotid artery intima-media thickness （IMT） in patients with essential hypertension. Methods Eighty hypertensive patients were randomly divided into the observation group of 40 cases, with the antihypertensive drug and rosuvastatin calcium 10 mg orally 1 time a day, 40 patients in control group only received the antihypertensive drug. Before treatment, after 1 months, 6 months and 12 months of treatment, 2 groups of patient＇s high sensitivity C reactive protein （hs-CRP）, homocysteine （ Hcy）, blood pressure, pulse pressure index and intima media thickness were measured and recorded. Results No statistical significance differences of before treatment blood pressure, PPI, serum hs-CRP, Hcy and IMT were found between the 2 groups （ P 〉 0.05 ）. Compared with before treatment, after 1 months of treatment, brachial artery systolic blood pressure, PP in the 2 groups were significantly decreased （ P 〈 0.05 ） , and diastolic blood pressure did not change significantly; after 12 months of treatment, the PPI in control group revealed statistical significance differences （ P 〈 0.05 ）, after 1 months of treatment, the observation group＇ s PPI significantly reduced （ P 〈 0.05 ）. Compared with the control group, after 6 months of treatment, the observation group＇s PP and systolic blood pressure decreased more significantly （ P 〈 0.05）, and treatment for 1, 6, 12 months later, compared with the same period control group, PPI in the observation group had significant difference （ P 〈 0.05）. The observation group after treatment, serum hs-CRP, Hcy concentration and IMT were significantly decreased （ P 〈 0.05 ）, compared with the control group, the observation group＇ s hs-CRP had significant differences at the treatment of 1,6,12 months （ P 〈 0.05） ; after treatment for 6,12 months, Hcy in the observation group had statistical significance difference

关 键 词：高血压 瑞舒伐他汀 血管活性物质 脉压指数 内膜中层厚度 

分 类 号：R544.1[医药卫生—心血管疾病]